The Valley Desk

NCT06082167 · Interventional trial

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Overall registry status Active not recruiting

Phase 2 · Phase 3

Conditions Head and Neck Squamous Cell Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov